Watch as Virginia Kaklamani, MD, and E. Shelley Hwang, MD, discuss the latest breakthroughs in breast cancer care, including promising trials with the potential to lead to FDA approvals and a novel approach to treating DCIS. These insights from the San Antonio Breast Cancer Symposium highlight exciting progress in therapies and strategies shaping the future of breast oncology.
In this video, Mikkael A. Sekeres, MD, shares insights from the ASH 2024 meeting on groundbreaking studies in hematology, including promising results for pediatric ALL treatments and the potential of early intervention in myeloma. Dr. Satwanilapur discusses the five-year update on Axocell therapy for indolent lymphoma, demonstrating remarkable long-term survival and remission outcomes. Tune in for the latest breakthroughs in hematologic cancer treatments.
Source : https://pubmed.ncbi.nlm.nih.gov/37341952/
Outcomes for children with acute lymphoblastic leukemia (ALL) have improved worldwide to >85%. For those who relapse, outcomes have remained static at ~50% making relapsed acute lymphoblastic leukemia one of...
Outcomes for children with relapsed acute lymphoblastic leukemia (ALL) remain poor. Advances in immunotherapies, cellular therapies, and precision oncology are crucial for improving treatment and outcomes, especially for poor responders.
Source : https://pubmed.ncbi.nlm.nih.gov/38178117/
Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological malignancies. Compared to our knowledge of B-cell tumors, our understanding of T-cell leukemia and lymphoma remains less advanced,...
This review explores mechanisms of treatment resistance in peripheral T-cell lymphoma (PTCL), including tumor heterogeneity, microenvironment, and signaling pathways, and discusses drugs and ongoing clinical trials targeting resistance.
Source : https://pubmed.ncbi.nlm.nih.gov/39000399/
Histiocytic sarcoma (HS) is an extremely rare but aggressive hematopoietic malignancy, and the prognosis has been reported to be rather unfavorable with a median overall survival of merely 6 months....
A 58-year-old woman with histiocytic sarcoma (HS) and follicular lymphoma was treated with Daratumumab, Pazopanib, chemotherapy, radiotherapy, and Tislelizumab, achieving partial remission for 22 months and overall survival of 32 months.